Anticoagulant Reversal Drug Market Research Report by Product (Andexxa, Idarucizumab, Protamine, Tranexamic Acid, and Vitamin K), by Distribution (Hospital Pharmacies and Retail Pharmacies) - Global Forecast to 2025 - Cumulative Impact of COVID-19

Anticoagulant Reversal Drug Market Research Report by Product (Andexxa, Idarucizumab, Protamine, Tranexamic Acid, and Vitamin K), by Distribution (Hospital Pharmacies and Retail Pharmacies) - Global Forecast to 2025 - Cumulative Impact of COVID-19

The Global Anticoagulant Reversal Drug Market is expected to grow from USD 460.15 Million/EUR 403.46 Million in 2020 to USD 785.44 Million/EUR 688.69 by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 11.28%.

Market Segmentation & Coverage:

This research report categorizes the Anticoagulant Reversal Drug to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the Anticoagulant Reversal Drug Market studied across Andexxa, Idarucizumab, Protamine, Tranexamic Acid, and Vitamin K.

Based on Distribution, the Anticoagulant Reversal Drug Market studied across Hospital Pharmacies and Retail Pharmacies.

Based on Geography, the Anticoagulant Reversal Drug Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Anticoagulant Reversal Drug Market including Amneal Pharmaceuticals, Inc., AstraZeneca PLC, Bausch Health Companies, Inc., BioVascular Inc, Boehringer Ingelheim GmbH, C.H. Boehringer Sohn AG & Co. KG, Cadila Healthcare Limited, CSL Limited, Daiichi Sankyo Company, Limited, Dr Reddy’s Laboratories Ltd,, Eli Lilly and Company, Fresenius Kabi AG, Genentech Inc, Hikma Pharmaceuticals PLC, Octapharma AG, Otsuka Pharmaceutical Co, Perosphere Pharmaceuticals, Inc. by AMAG Pharmaceuticals, Inc, Pfizer, Inc., and Portola Pharmaceuticals, Inc..

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anticoagulant Reversal Drug Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Anticoagulant Reversal Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Anticoagulant Reversal Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Anticoagulant Reversal Drug Market?
4. What is the competitive strategic window for opportunities in the Global Anticoagulant Reversal Drug Market?
5. What are the technology trends and regulatory frameworks in the Global Anticoagulant Reversal Drug Market?
6. What are the modes and strategic moves considered suitable for entering the Global Anticoagulant Reversal Drug Market?


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. Research Methodology
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Product Outlook
3.4. Distribution Outlook
3.5. Geography Outlook
3.6. Competitor Outlook
4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19
4.3. Geographic Growth Opportunities
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in the prevalence of atrial fibrillation, intracranial hemorrhages, and Gastrointestinal hemorrhages
5.1.1.2. Rise in the product launches due to accelerated drug approval initiative by FDA
5.1.2. Restraints
5.1.2.1. Stringent regulatory reforms due to severe risks associated with the reversal of anticoagulation
5.1.3. Opportunities
5.1.3.1. Introduction of new technology add-on payment (NTAP)
5.1.4. Challenges
5.1.4.1. Availability of the high cost of the patent drugs
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. Global Anticoagulant Reversal Drug Market, By Product
6.1. Introduction
6.2. Andexxa
6.3. Idarucizumab
6.4. Protamine
6.5. Tranexamic Acid
6.6. Vitamin K
7. Global Anticoagulant Reversal Drug Market, By Distribution
7.1. Introduction
7.2. Hospital Pharmacies
7.3. Retail Pharmacies
8. Americas Anticoagulant Reversal Drug Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Anticoagulant Reversal Drug Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. South Korea
9.10. Thailand
10. Europe, Middle East & Africa Anticoagulant Reversal Drug Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Amneal Pharmaceuticals, Inc.
12.2. AstraZeneca PLC
12.3. Bausch Health Companies, Inc.
12.4. BioVascular Inc
12.5. Boehringer Ingelheim GmbH
12.6. C.H. Boehringer Sohn AG & Co. KG
12.7. Cadila Healthcare Limited
12.8. CSL Limited
12.9. Daiichi Sankyo Company, Limited
12.10. Dr Reddy’s Laboratories Ltd,
12.11. Eli Lilly and Company
12.12. Fresenius Kabi AG
12.13. Genentech Inc
12.14. Hikma Pharmaceuticals PLC
12.15. Octapharma AG
12.16. Otsuka Pharmaceutical Co
12.17. Perosphere Pharmaceuticals, Inc. by AMAG Pharmaceuticals, Inc
12.18. Pfizer, Inc.
12.19. Portola Pharmaceuticals, Inc.
13. Appendix
13.1. Discussion Guide

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook